Skip to main content

Table 1 Demographic and clinical characteristics for SZ patients and HC

From: Deficits of perceived spatial separation induced prepulse inhibition in patients with schizophrenia: relationships to symptoms and neurocognition

Variable

HC

SZ

t/χ2

p

N = 50

N = 75

Gender (M/F)

38/12

54/21

0.25

0.68a

Smoke

 Ratio

68.0%

60.0%

0.83

0.45a

 Cigarettes per day

6.6 ± 8.8

7.3 ± 8.6

0.45

0.65b

Age (year)

42.9 ± 8.0

44.9 ± 6.7

1.57

0.12b

Education (year)

11.6 ± 3.2

10.8 ± 2.6

0.02

0.89b

Age of onset (year)

 

24.8 ± 6.7

  

Recurrence times

 

4.7 ± 2.5

  

Duration (year)

 

19.5 ± 8.4

  

Medication

 FGA, n (%)

 

14 (18.7)

  

 SGA, n (%)

 

40 (53.3)

  

 FGA + SGA, n (%)

 

21 (18.0)

  

 CPZ(mg/day)

 

300.6 ± 247.0

  

PANSS score

 Total

 

62.3 ± 13.5

  

 Positive

 

12.6 ± 4.7

  

 Negative

 

19.7 ± 6.5

  

 General

 

29.9 ± 5.7

  
  1. Note: Data are expressed as mean ± SD, SD standard deviation, SZ schizophrenia patients, HC healthy controls, CPZ chlorpromazine equivalent dosage
  2. PANSS: positive and negative syndrome scale; a indicates p value for chi-square test; b indicates p value for independent sample t-test.